The Future of Drug Monitoring: Integrating Advanced Bioanalytical Techniques into Healthcare

Authors

  • B. S Ashok Kumar
  • N. S. Disha
  • Mohammed Khalid

DOI:

https://doi.org/10.52783/jns.v14.3363

Keywords:

Bioanalysis, Drug Monitoring, UPLC, LC-MS/MS, High-Resolution Mass Spectrometry, AI

Abstract

Advances in bioanalytical techniques have revolutionized drug monitoring, enabling more precise and personalized therapeutic interventions. While tried and true methods and basics are super important, they just don't cut it anymore for doctors and patients alike. They just don't have enough finesse, efficiency, or speed to keep up with all the modern needs of healthcare. Clinically speaking, modern medicine wants quick, specific results and others of that ilk. The emergence of next-generation bioanalytical techniques, including advanced chromatographic methods (such as UPLC and LC-MS/MS), high-resolution mass spectrometry (HRMS), spectroscopic innovations (FTIR, Raman, NMR), biosensors, microfluidics, nanotechnology, and AI-driven analytics, has significantly enhanced drug monitoring capabilities. These new innovations detect levels and metabolite biomarkers of medicines super fast and accurately. This helps doctors to offer treatments that really match individual people and do better monitoring of which therapies are working for patients. Being so quick and precise, this lets doctors make fantastic clinical decisions that really benefit patients on an individual level. The integration of these technologies with electronic health records (EHR) allows for seamless monitoring of drug-drug interactions and patient-specific therapeutic adjustments. While they have amazing potential, there are challenges like high costs, complicated processes, regulatory red tape, and they really require skilled people. Furthermore, issues like sample preparation, matrix interferences, and standardization must be addressed to ensure reliable, reproducible results. Looking ahead, integrating approaches using different types of research data is going to be really important. We're also going to see bedside monitoring the equipment doctors use in their work room get smaller and more manageable. Alongside that we'll keep developing and improving software that doctors can use at the front line when they're thinking about prescribing medications in real time and making decisions. That's going to play a huge role in the future evolution of monitoring drugs that people are taking. Using block chain to keep data as solid as a rock comes to have a big advantage too it can supercharge security and keep everyone in the loop for drug monitoring too. This review highlights key advancements, clinical applications, and future trends in next-generation bioanalytical techniques, emphasizing their potential to transform patient care and therapeutic efficacy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Smith A, Jones B. The role of therapeutic drug monitoring in clinical practice. Clin Pharmacol Ther. 105:345-356, 2020.

Brown C, Taylor D. Drug monitoring in special populations: challenges and opportunities. J Clin Med. 10:1123, 2021.

Patel P, et al. Limitations of traditional bioanalytical techniques and the need for innovation. Anal Bioanal Chem. 411:1545-1560, 2019.

Chen L, et al. Sample preparation challenges in traditional drug monitoring techniques. J Chromatogr B. 1156:122346, 2020.

Gonzalez R, et al. Cost-effectiveness of bioanalytical methods in healthcare settings. PharmacoEconomics. 36:843-855, 2018.

Zhang X, et al. Advances in LC-MS/MS for therapeutic drug monitoring. Mass Spectrom Rev. 41:234-256, 2022.

Park J, et al. Application of biosensors in drug monitoring. Biosens Bioelectron. 178:113010, 2021.

Nguyen T, et al. Integration of AI in bioanalytical techniques for precision medicine. Nat Biomed Eng. 7:23-35, 2023.

Glick D. Analytical methods of protein analysis. Clin Chim Acta. 1:425-436, 1956.

Snyder LR, Kirkland JJ, Dolan JW. Introduction to Modern Liquid Chromatography. 3rd ed. Wiley, 2010.

Northen TR, Stenken JA. Advances in Chromatography-Mass Spectrometry Couplings for Bioanalysis. J Chromatogr A. 1132:1-12, 2006.

Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Immunochemistry. 8:871-874, 1971.

Whitesides GM. The origins and the future of microfluidics. Nature. 442:368-373, 2006.

Sidhartha A, Rani N. Quantification of pharmaceuticals in biological matrices by LC-MS/MS: Applications in pharmacokinetics and drug monitoring. Bioanalysis. 11:711-726, 2019.

U.S. Food and Drug Administration. Bioanalytical method validation guidance for industry. 2018. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-method-validation-guidance-industry.

Makarov A, Scigelova M. Coupling liquid chromatography to Orbitrap mass spectrometry. J Chromatogr A. 1217:3938-3945, 2010.

Kaufmann A. Combining Orbitrap and time-of-flight mass spectrometry for comprehensive analysis in drug testing. Anal Chim Acta. 862:50-62, 2015.

Korfmacher WA. Principles and applications of LC-MS in new drug discovery. Drug Discov Today. 10:1357-1367, 2005.

Dettmer K, Aronov PA, Hammock BD. Mass spectrometry-based metabolomics. Mass Spectrom Rev. 26:51-78, 2007.

He Y, Xu G. Recent advancements in Ultra-Performance Liquid Chromatography (UPLC) for pharmaceutical analysis. Anal Chim Acta. 636:1-14, 2009.

Matuszewski BK, Constanzer ML, Chavez-Eng CM. LC-MS/MS in the pharmaceutical industry. Pharm Tech. 32:14-26, 2008.

Xie Y, Zhang L, Sun Y. Supercritical Fluid Chromatography for pharmaceutical analysis. J Chromatogr A. 1164:75-84, 2007.

Bonfiglio R, King RC, Brown SD, et al. Multi-dimensional chromatography in drug analysis. J Chromatogr A. 1067:43-56, 2005.

Ozdemir F, et al. Application of FTIR for pharmaceutical analysis. Int J Pharm. 436:1-9, 2012.

Matias S, et al. Raman spectroscopy for drug analysis: Challenges and applications. Drug Test Anal. 8:327-336, 2016.

Kumar A, et al. Nuclear Magnetic Resonance (NMR) in drug metabolism. Anal Bioanal Chem. 396:27-38, 2010.

Wang J. Electrochemical biosensors for therapeutic drug monitoring. Electroanalysis. 28:290-299, 2016.

Yan Z, et al. Wearable and implantable biosensors for drug monitoring. J Control Release. 296:144-153, 2019.

Choi Y, et al. Paper-based and smartphone-integrated biosensors for healthcare. Lab Chip. 17:1452-1463, 2017.

Hwang G, et al. Microfluidic devices for point-of-care testing. Microfluid Nanofluid. 21:85, 2017.

Barman I, et al. Integration of microfluidics with mass spectrometry. Anal Chem. 87:4508-4515, 2015.

Tuchin V. Personalized medicine: Microfluidic approaches. Biomicrofluidics. 11:013302, 2017.

Zhang Y, et al. Nanoparticles in therapeutic drug monitoring. Anal Chem. 90:3147-3157, 2018.

Patil S, et al. Applications of nanomaterials in drug monitoring. J Nanobiotechnol. 14:45, 2016.

Ahmed A, et al. Quantum dots in drug detection. Nanomedicine. 14:637-645, 2018.

Kim J, et al. AI-driven predictive analytics in pharmacokinetics. Pharmacokinetics. 35:1-8, 2020.

Hughes M, et al. Machine learning for personalized drug monitoring. J Pharm Sci. 107:1831-1839, 2018.

Li X, et al. Automation in bioanalytical workflows for high-throughput screening. Trends Anal Chem. 116:133-141, 2019.

Gibson GR, et al. Personalized medicine: A review of bioanalytical tools for individualized therapy. Clin Chem. 61:641-650, 2015.

Patel V, et al. Integration of bioanalytical technologies with electronic health records. J Med Syst. 40:290, 2016.

Norrby SR, et al. Drug-drug interactions in therapeutic drug monitoring: Current approaches and new challenges. J Clin Pharm Ther. 43:533-539, 2018.

FDA. Guidance for Industry: Bioanalytical Method Validation. US FDA, 2018.

International Council for Harmonisation. ICH E6 (R2) Good Clinical Practice: Integrated Addendum to ICH E6 (R1). International Conference on Harmonisation, 2016.

EMEA. Scientific Guideline on the Validation of Bioanalytical Methods. European Medicines Agency, 2011.

Thamlikitkul V, et al. Therapeutic drug monitoring of antibiotics: Concepts and clinical applications. J Antimicrob Chemother. 70:1002-1007, 2015.

Gonsalves WI, et al. Therapeutic drug monitoring of antiepileptic drugs: Current trends and future perspectives. Seizure. 44:58-64, 2017.

Lu X, et al. Advanced bioanalytical techniques for oncology drug monitoring. J Pharm Biomed Anal. 138:166-175, 2017.

Olfson M, Blanco C, Wang S, et al. National trends in mental health care for children, adolescents, and young adults. JAMA Psychiatry. 71:330-338, 2014.

Boucher HW, et al. Therapeutic drug monitoring of antimicrobial agents. Clin Infect Dis. 69:425-435, 2019.

Heitmeier S, et al. Therapeutic drug monitoring in pediatrics and geriatrics. Pediatr Drugs. 20:297-304, 2018.

Venkatraman R, et al. The role of next-generation bioanalytical methods in personalized medicine. J Pharm Biomed Anal. 162:200-212, 2019.

Wang L, et al. High-throughput and portable analytical techniques for bedside diagnostics. Trends Anal Chem. 130:115959, 2020.

He Z, et al. Integration of multi-omics approaches in therapeutic drug monitoring. Clin Chem Lab Med. 56:1472-1483, 2018.

Anastasopoulou L, et al. AI-driven analytics for drug monitoring in clinical practice. AI in Health Care. 2:100-110, 2021.

Zhang M, et al. Blockchain technology for ensuring data integrity in medical records. J Med Syst. 45:54, 2021

Downloads

Published

2025-04-10

How to Cite

1.
Ashok Kumar BS, Disha NS, Khalid M. The Future of Drug Monitoring: Integrating Advanced Bioanalytical Techniques into Healthcare. J Neonatal Surg [Internet]. 2025Apr.10 [cited 2025Nov.4];14(13S):695-704. Available from: https://jneonatalsurg.com/index.php/jns/article/view/3363

Similar Articles

You may also start an advanced similarity search for this article.